May 13, 2020 / 10:27 PM / 17 days ago

BRIEF-Exelixis Announces Results From Trial Of Cabozantinib In Combination With Atezolizumab In Multiple Advanced Solid Tumor Types

May 13 (Reuters) - Exelixis Inc:

* EXELIXIS ANNOUNCES RESULTS FROM COSMIC-021 TRIAL OF CABOZANTINIB IN COMBINATION WITH ATEZOLIZUMAB IN MULTIPLE ADVANCED SOLID TUMOR TYPES

* EXELIXIS INC - 27% OBJECTIVE RESPONSE RATE SEEN IN IMMUNE CHECKPOINT INHIBITOR-PRETREATED NON-SMALL CELL LUNG CANCER COHORT 7 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below